Semax

Little activity

Semax appears in 137 indexed publications going back to 1991, including 5 in the past twelve months. No clinical trials are registered on ClinicalTrials.gov.

137

Indexed publications

Past 12 months, against 7 the year before

Registered clinical trials

10,453

Monthly readers on Wikipedia, down 6%

On This Figure
A peptide context filter is required, since "semax" also matches the statistical notation SE(max).

Research Activity

Publication history

How much work has been indexed each year, from Europe PMC. Momentum is measured over a trailing twelve months rather than calendar years, so a partial current year never reads as a decline.

20152026

Publications per year. The final bar is the current year, still in progress.

Indexed publications per year
2015	5
2016	4
2017	6
2018	3
2019	1
2020	6
2021	9
2022	2
2023	4
2024	3
2025	7
2026	2

Public Attention

Who is looking it up

Monthly readers of the Semax article on English Wikipedia. An independent measure of curiosity, which often moves quite differently from the evidence.

2025-082026-07

Clinical Trials

The registered pipeline

No clinical trials are registered for this compound on ClinicalTrials.gov. That is common for peptides with no remaining composition of matter patent: without exclusivity there is rarely a sponsor to fund registered trials, so the evidence stays preclinical.

References

Most recent work

The newest indexed records mentioning Semax, listed by publication date. Titles are shown as published and link to their source. Inclusion here is a record of what exists, not a judgement of what it shows.

2026-04-07·Frontiers in aging
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, Shypilova I, Bolgova O. et al.
2026-01-02·Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA. et al.
2025-09-21·Neuropeptides
Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases
Giri S, Chandra P. et al.
2025-07-21·British journal of pharmacology
Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice
Liu R, Chen Y, Huang H et al.
2025-10-01·Acta naturae
The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease
Radchenko AI, Kuzubova EV, Apostol AA et al.
2025-08-01·Bulletin of experimental biology and medicine
The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons
Kolbaev SN, Sharonova IN, Skrebitsky VG. et al.
2025-06-28·International journal of molecular sciences
Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage
Filippenkov IB, Shpetko YY, Ales DA et al.
2025-06-03·Bioinorganic chemistry and applications
Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing
Tomasello MF, Di Rosa MC, Naletova I et al.

In the Catalogue

Semax available from Polaris Research

Semax 10mg

Brain Function

$0.99View product

Supplied as research materials for laboratory use. Free express delivery Australia wide.

Sources

Publication data from Europe PMC. Clinical trial data from ClinicalTrials.gov, U.S. National Library of Medicine. Public attention from Wikimedia pageview data. Evidence grades from reptides.co. We report counts and dates from these sources and link every record to its origin, we do not summarise findings. Last synced 2026-08-02.